MP 136
Alternative Names: MP-136Latest Information Update: 15 May 2012
Price :
$50 *
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lipid metabolism disorders
Most Recent Events
- 15 May 2012 Discontinued - Phase-I for Lipid metabolism disorders in European Union (unspecified route)
- 14 Oct 2009 Phase-I clinical trials in Lipid metabolism disorders in European Union (unspecified route)